# A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity

> **NCT05621616** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 7 (actual)

## Conditions studied

- Neurogenic Detrusor Overactivity

## Interventions

- **DRUG:** mirabegron

## Key facts

- **NCT ID:** NCT05621616
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-28
- **Primary completion:** 2026-02-16
- **Final completion:** 2026-09-30
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05621616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05621616, "A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05621616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*